BeStock  
股票 › 生物科技 › MESO

美索博拉斯特 MESO

美股市值排名 #2796生物科技
$14.27 +$0.17 (+1.21%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $14.27 0.00%
开盘$14.00
昨收$14.10
当日区间$13.82 – $14.31
成交量192.8K
市值$1.86B
市盈率(TTM)–
股息率–

MESO 相关新闻

匹配 Mesoblast 或代码 MESO 的头条新闻,按最新排序。

  • Maxim Group Maintains Mesoblast(MESO.US) With Buy Rating, Maintains Target Price $35Market news · 26 Sep 2026 · 直接提及
  • Piper Sandler Maintains Mesoblast(MESO.US) With Buy Rating, Raises Target Price to $39 正面Market news · 27 Aug 2026 · 直接提及
  • Mesoblast (MESO.US) will release its earnings report after the market close on August 26.Market news · 24 Aug 2026 · 直接提及
  • Piper Sandler Maintains Mesoblast(MESO.US) With Buy Rating, Maintains Target Price $35Market news · 10 Apr 2026 · 直接提及
  • Piper Sandler Maintains Mesoblast(MESO.US) With Buy Rating, Raises Target Price to $35 正面Market news · 2 Mar 2026 · 直接提及
  • Maxim Group Maintains Mesoblast(MESO.US) With Buy Rating, Maintains Target Price $30Market news · 6 Sep 2025 · 直接提及
  • Piper Sandler Maintains Mesoblast(MESO.US) With Buy Rating, Maintains Target Price $24Market news · 10 Sep 2025 · 直接提及
  • Piper Sandler Maintains Mesoblast(MESO.US) With Buy Rating, Raises Target Price to $24 正面Market news · 7 Feb 2025 · 直接提及
  • Maxim Group Maintains Mesoblast(MESO.US) With Buy Rating, Raises Target Price to $35 正面Market news · 9 Oct 2025 · 直接提及
  • Maxim Group Upgrades Mesoblast(MESO.US) to Buy Rating, Cuts Target Price to $12 中性Market news · 24 Sep 2024 · 直接提及
  • Piper Sandler Maintains Mesoblast(MESO.US) With Buy Rating, Announces Target Price $11Market news · 29 Aug 2024 · 直接提及
  • MESO NUMISMATICS INC | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filingSEC · 23 Aug 2024 · 直接提及
  • MESO NUMISMATICS INC | 10-Q: Q2 2024 Earnings ReportSEC · 15 Aug 2024 · 直接提及
  • Piper Sandler Upgrades Mesoblast(MESO.US) to Buy Rating 正面Market news · 24 Jul 2024 · 直接提及
  • MESO NUMISMATICS INC | 8-K: Current reportSEC · 23 May 2024 · 直接提及

讨论区

暂无评论——快来第一个聊聊 MESO。

登录后参与讨论。

Scroll to Top